Nonsteroidal anti-inflammatory drugs and the heart: What is the danger?

Congestive Heart Failure

Volumn 14, Issue 2, 2008, Pages 75-82

  Mukherjee, Debabrata ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HEART; HUMAN; REVIEW; RISK FACTOR; THROMBOEMBOLISM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; HEART; HUMANS; RISK FACTORS; THROMBOEMBOLISM;

EID: 44449125803     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2008.07453.x     Document Type: Article

References (48)

1. Abraham NS, Graham DY. NSAIDs and gastrointestinal complications: new clinical challenges. Expert Opin Pharmacother. 2005;6:2681-2689.
2. Mukherjee D. Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem Pharmacol. 2002;63:817-821.
3. Green GA. Understanding NSAIDs: from aspirin to COX-2. Clin Cornerstone. 2001;3:50-60.
4. Schmedtje JF Jr, Ji YS, Liu WL, et al. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem. 1997;272:601-608.
5. Belton O, Byrne D, Kearney D, et al. Cyclooxygenase-1 and -2-dependent prosta-cyclin formation in patients with atherosclerosis. Circulation. 2000;102:840-845.
6. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954-959.
7. Bombardier C, Laine L, Reicin A, et al; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520-1528
8. US Food and Drug Administration. Cardiovascular Safety Review of Rofecoxib. Gaithersburg, MD: FDA Advisory Committee; 2001.
9. US Food and Drug Administration. Statistical Reviewer Briefing Document for the Advisory Committee. Gaithersburg, MD: US Food and Drug Administration; 2001.
10. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365:475-481.
11. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092-1102.
12. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecox-ib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092-1102.
13. Nissen SE. Adverse cardiovascular effects of rofecoxib. N Engl J Med. 2006;355:203-204.
14. Topol EJ. Failing the public health-rofecoxib, Merck, and the FDA. N Engl J Med. 2004;351:1707-1709.
15. Kerr DJ, Dunn JA, Langman MJ, et al; VICTOR Trial Group. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med. 2007;357:360-369.
16. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247-1255.
17. Topol EJ. Arthritis medicines and cardiovascular events-"house of coxibs." JAMA. 2005;293:366-368.
18. Psaty BM, Potter JD. Risks and benefits of celecoxib to prevent recurrent adenomas. N Engl J Med. 2006;355:950-952.
19. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflam-matory drugs after acute myocardial infarction. Circulation. 2006;113:2906-2913.
20. Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation. 2006;113:1950-1957.
21. Topol EJ, Falk GW. A coxib a day won't keep the doctor away. Lancet. 2004;364:639-640.
22. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2003;125:1481-1492.
23. White WB, Strand V, Roberts R, et al. Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflamma-tory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Ther. 2004;11:244-250.
24. FitzGerald G. Valdecoxib meta-analysis signals significant cardiovascular risk. Paper presented at: American Heart Association Scientific Sessions 2004; New Orleans, LA; 2004.
25. Furberg CD, Psaty BM, FitzGerald GA. Parecoxib, valdecoxib, and cardiovascular risk. Circulation. 2005;111:249.
26. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296:1633-1644.
27. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634-1642.
28. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809-1817.
29. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003;361:573-574.
30. Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, et al. Nonsteroidal antiinflamma-tory drugs and the risk of myocardial infarction in the general population. Circulation. 2004;109:3000-3006.
31. Farkouh ME, Greenberg JD, Jeger RV, et al. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis. 2007;66:764-770.
32. Wang JG, Liu L, Zagato L, et al. Blood pressure in relation to three candidate genes in a Chinese population. J Hypertens. 2004;22:937-944.
33. Morrison A, Ramey DR, van Adelsberg J, et al. Systematic review of trials of the effect of continued use of oral non-selective NSAIDs on blood pressure and hypertension. Curr Med Res Opin. 2007;23(10):2395-2404.
34. Sowers JR, White WB, Pitt B, et al. The effects of cyclooxygenase-2 inhibitors and nonsteroi-dal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med. 2005;165:161-168.
35. Solomon DH, Schneeweiss S, Levin R, et al. Relationship between COX-2 specific inhibitors and hypertension. Hypertension. 2004;44:140-145.
36. Whelton A, White WB, Bello AE, et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002;90:959-963.
37. Whelton A, Fort JG, Puma JA, et al. Cyclooxygenase-2-specific inhibitors and car-diorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther. 2001;8:85-95.
38. Whelton A, Lefkowith JL, West CR, et al. Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. Kidney Int. 2006;70:1495-1502.
39. Palmer R, Weiss R, Zusman RM, et al. Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors. Am J Hypertens. 2003;16:135-139.
40. Wilson SL, Poulter NR. The effect of non-steroidal anti-inflammatory drugs and other commonly used non-narcotic analgesics on blood pressure level in adults. J Hypertens. 2006;24:1457-1469.
41. Kurth T, Hennekens CH, Sturmer T, et al. Analgesic use and risk of subsequent hypertension in apparently healthy men. Arch Intern Med. 2005;165:1903-1909.
42. Mamdani M, Juurlink DN, Lee DS, et al. cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004;363:1751-1756.
43. Hudson M, Rahme E, Richard H, et al. Risk of congestive heart failure with nonsteroi-dal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect? Arthritis Rheum. 2007;57:516-523.
44. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology {Oxford}. 2005;44:677-680.
45. Rao GH, Johnson GG, Reddy KR, et al. Ibuprofen protects platelet cyclooxyge-nase from irreversible inhibition by aspirin. Arteriosclerosis. 1 983;3:383-388.
46. Leese PT, Hubbard RC, Karim A, et al. Effects of celecoxib, a novel cyclooxyge-nase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol. 2000;40:124-132.
47. Nikanne E, Kokki H, Salo J, et al. Celecoxib and ketoprofen for pain management during tonsillectomy: a placebo-controlled clinical trial. Otolaryngol Head Neck Surg. 2005;132:287-294.
48. Becker RC. COX-2 inhibitors. Tex Heart Inst J. 2005;32:380-383.